| [1] |
Winthrop KL, Marras T, Adjemian J, et al. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U. S. managed care health plan, 2008—2015. Ann Am Thorac Soc, 2020, 17(2):178-185. doi:10.1513/AnnalsATS.201804-236OC.
doi: 10.1513/AnnalsATS.201804-236OC
pmid: 31830805
|
| [2] |
Prevots DR, Shaw PA, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med, 2010, 182(7): 970-976. doi:10.1164/rccm.201002-0310OC.
doi: 10.1164/rccm.201002-0310OC
URL
|
| [3] |
Lee H, Myung W, Koh WJ, et al. Epidemiology of nontuberculous mycobacterial infection, South Korea, 2007—2016. Emerg Infect Dis, 2019, 25(3):569-572. doi:10.3201/eid2503.181597.
doi: 10.3201/eid2503.181597
URL
|
| [4] |
Kumar K, Loebinger MR. Nontuberculous mycobacterial pulmonary disease: clinical epidemiologic features, risk Factors, and diagnosis: the nontuberculous mycobacterial series. Chest, 2022, 161(3):637-646. doi:10.1016/j.chest.2021.10.003.
doi: 10.1016/j.chest.2021.10.003
URL
|
| [5] |
Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis, 1990, 142(4):940-953. doi:10.1164/ajrccm/142.4.940.
doi: 10.1164/ajrccm/142.4.940
URL
|
| [6] |
Hwang JA, Kim S, Jo KW, et al. Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course. Eur Respir J, 2017, 49(3): 1600537. doi:10.1183/13993003.00537-2016.
doi: 10.1183/13993003.00537-2016
|
| [7] |
Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J, 2020, 56(1):2000535. doi:10.1183/13993003.00535-2020.
doi: 10.1183/13993003.00535-2020
|
| [8] |
初乃惠, 段鸿飞. 非结核分枝杆菌病诊断与治疗. 北京: 人民卫生出版社, 2019:120-140.
|
| [9] |
Adjemian J, Prevots DR, Gallagher J, et al. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease. Ann Am Thorac Soc, 2014, 11(1):9-16. doi:10.1513/AnnalsATS.201304-085OC.
doi: 10.1513/AnnalsATS.201304-085OC
pmid: 24236749
|
| [10] |
Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med, 2007, 101(1): 130-138. doi:10.1016/j.rmed.2006.04.002.
doi: 10.1016/j.rmed.2006.04.002
URL
|
| [11] |
Kwak N, Dalcolmo MP, Daley CL, et al. Mycobacterium abscessus pulmonary disease: individual patient data meta-analysis. Eur Respir J, 2019, 54(1): 1801991. doi:10.1183/13993003.01991-2018.
doi: 10.1183/13993003.01991-2018
|
| [12] |
Clinical and Laboratory Standards Institute. Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes. 3rd ed. Wayne: Clinical and Laboratory Standards Institute, 2018.
|
| [13] |
van Ingen J, Aksamit T, Andrejak C, et al. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J, 2018, 51(3): 1800170. doi:10.1183/13993003.00170-2018.
doi: 10.1183/13993003.00170-2018
|
| [14] |
Jhun BW, Kim SY, Moon SM, et al. Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease. Am J Respir Crit Care Med, 2018, 198(10):1322-1330. doi:10.1164/rccm.201802-0321OC.
doi: 10.1164/rccm.201802-0321OC
URL
|
| [15] |
Koh WJ, Jeong BH, Kim SY, et al. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. Clin Infect Dis, 2017, 64(3):309-316. doi:10.1093/cid/ciw724.
doi: 10.1093/cid/ciw724
URL
|
| [16] |
Flume PA, Griffith DE, Chalmers JD, et al. Development of Drugs for Nontuberculous Mycobacterial Disease: Clinicians’ Interpretation of a US Food and Drug Administration Workshop. Chest, 2021, 159(2):537-543. doi:10.1016/j.chest.2020.08.2055.
doi: 10.1016/j.chest.2020.08.2055
URL
|
| [17] |
中华医学会结核病学分会. 非结核分枝杆菌病诊断与治疗指南(2020年版). 中华结核和呼吸杂志, 2020, 43(11):918-946. doi:10.3760/cma.j.cn112147-20200508-00570.
doi: 10.3760/cma.j.cn112147-20200508-00570
|
| [18] |
Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax, 2017, 72(Suppl 2):ii1-ii64. doi:10.1136/thoraxjnl-2017-210927.
doi: 10.1136/thoraxjnl-2017-210927
|
| [19] |
Griffith DE, Eagle G, Thomson R, et al. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med, 2018, 198(12):1559-1569. doi:10.1164/rccm.201807-1318OC.
doi: 10.1164/rccm.201807-1318OC
URL
|
)
京公网安备11010202007215号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
